Agenus Initiates Botensilimab Phase II ACTIVATE Trials in Advanced MSS Colorectal Cancer and Advanced Melanoma

Agenus announced the initiation of a global Phase II program of botensilimab, an Fc-enhanced anti-CTLA-4 that activates innate and adaptive immune responses.